The Nobelpharma auditory system bone-anchored hearing aid: the Edmonton experience.

Abstract

The unique ability of titanium to osseointegrate has been utilized in clinical practice for bone-anchored hearing aids in Sweden since 1977. The percutaneous design by Nobelpharma has been shown to be useful not only for pure conductive hearing loss but also mixed losses with a bone pure tone average of 45 dB (60 dB with the HC220). We examine our experience, since May 1991, with 15 patients aged 8 to 73 years, including indications, complications, and both objective and subjective results. In addition, we have found the second stage can be successfully completed during the initial anesthetic without the usual delay of 3 months for many patients. We believe the technique for osseointegration is a suitable addition to the armamentarium for the otolaryngologist against hearing loss.

• Authors: D R Liepert, J C DiToppa
• Journal: The Journal of otolaryngology (J Otolaryngol) Vol. 23 Issue 6 Pg. 411-8 (Dec 1994) ISSN: 0381-6605 [Print] Canada
• PMID: 7897770 (Publication Type: Journal Article)

Chemical References

• Titanium

Topics

• Adolescent
• Adult
• Aged
• Child
• Ear Diseases (complications, physiopathology)
• Equipment Design
• Follow-Up Studies
• Hearing Aids
• Hearing Loss, Conductive (diagnosis, etiology, rehabilitation)
• Humans
• Middle Aged
• Postoperative Complications
• Retrospective Studies
• Skin Tests
• Speech Reception Threshold Test
• Surveys and Questionnaires
• Sweden
• Titanium